CFO Apel sells 13.1K shares at $71.35 avg, retains 162.9K; stock near 52-week peak at $73.91
Apel, Arrowhead Pharmaceuticals' CFO, executed 3 separate sales totaling 13,095 shares for $934,285.13, reducing holdings by 7.4% to 162.9K shares. The trades were executed at a blended average price of $71.35 across April 22, 2026, occurring when the stock is trading at $73.91, just 0.7% below its 52-week high of $74.40 and up 21.6% over the past 30 days. While the company has returned to profitability in its latest quarter with $30.8M net income on $264.0M revenue and demonstrated strong annual revenue growth of 23258.2%, the broader context shows the company had been unprofitable over its most recent full fiscal year. The CFO retains substantial holdings post-transaction, and the sales represent a modest portfolio reduction rather than a material exit.